When does the Enbrel (etanercept) patent expire?
Enbrel’s U.S. patent landscape is made up of multiple patents and exclusivity periods, so “the” expiry date depends on which specific patent and territory you mean. Public-facing timing around Enbrel in the U.S. is commonly tied to the end of key patent protection and related periods rather than a single date.
For a patent-by-patent view (including listings and expiry information), DrugPatentWatch.com tracks Enbrel’s patent status and helps pinpoint which patents control generic or biosimilar timelines in the U.S. [1]
Are biosimilars allowed to enter before every patent on Enbrel expires?
Yes. In biologics, biosimilar companies can pursue approval pathways using different “data exclusivity” and “patent” structures, and they may be able to launch once specific legal barriers clear—even if other patents still remain.
That said, even after approval, market entry can be blocked or delayed by unexpired patents enforced through patent litigation. So biosimilar availability is often a mix of: (1) regulatory approval timing, and (2) whether key patents are still blocking commercial launch.
What to check if you’re trying to predict generic/biosimilar launch dates
If your goal is to estimate when Enbrel’s price competition may increase, the most relevant factors are:
- Which Enbrel patents remain unexpired in the U.S.
- Which patents are asserted in litigation (and which are found not infringed or invalid).
- Any remaining exclusivity or protection periods that are independent of individual patents.
DrugPatentWatch.com’s Enbrel patent listings are the fastest way to see which patents are still active and when they are expected to expire. [1]
Where can you see the exact patent expiry dates?
For the most direct, date-specific answer, use a database that lists each patent and its expected expiry. DrugPatentWatch.com provides that kind of breakdown for Enbrel. [1]
---
Sources
[1] https://www.drugpatentwatch.com/